These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1526337)

  • 1. Nonenzymatic glycosylation of macromolecules. Prospects of pharmacologic modulation.
    Brownlee M
    Diabetes; 1992 Oct; 41 Suppl 2():57-60. PubMed ID: 1526337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycosylation of proteins and microangiopathy.
    Brownlee M
    Hosp Pract (Off Ed); 1992 Feb; 27 Suppl 1():46-50. PubMed ID: 1347540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.
    Brownlee M; Vlassara H; Kooney A; Ulrich P; Cerami A
    Science; 1986 Jun; 232(4758):1629-32. PubMed ID: 3487117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current therapeutic interventions in the glycation pathway: evidence from clinical studies.
    Engelen L; Stehouwer CD; Schalkwijk CG
    Diabetes Obes Metab; 2013 Aug; 15(8):677-89. PubMed ID: 23279611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPARC gene expression is increased in diabetes-related mesenteric vascular hypertrophy.
    Jandeleit-Dahm K; Rumble J; Cox AJ; Kelly DJ; Dziadek M; Cooper ME; Gilbert RE
    Microvasc Res; 2000 Jan; 59(1):61-71. PubMed ID: 10625572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypothesis: the "metabolic memory", the new challenge of diabetes.
    Ceriello A
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S2-6. PubMed ID: 20115927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aminoguanidine suppresses basal macromolecular extravasation during diabetes mellitus.
    Mayhan WG; Sharpe GM
    Microvasc Res; 2000 Jan; 59(1):52-60. PubMed ID: 10625571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced glycation end products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy?
    McLennan SV; Kelly DJ; Schache M; Waltham M; Dy V; Langham RG; Yue DK; Gilbert RE
    Kidney Int; 2007 Aug; 72(4):481-8. PubMed ID: 17554258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes.
    Soulis T; Sastra S; Thallas V; Mortensen SB; Wilken M; Clausen JT; Bjerrum OJ; Petersen H; Lau J; Jerums G; Boel E; Cooper ME
    Diabetologia; 1999 Apr; 42(4):472-9. PubMed ID: 10230652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation.
    Tilton RG; Chang K; Hasan KS; Smith SR; Petrash JM; Misko TP; Moore WM; Currie MG; Corbett JA; McDaniel ML
    Diabetes; 1993 Feb; 42(2):221-32. PubMed ID: 7678825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced glycosylation end-products in experimental murine diabetic nephropathy: effect of islet isografting and of aminoguanidine.
    Nicholls K; Mandel TE
    Lab Invest; 1989 Apr; 60(4):486-91. PubMed ID: 2496273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Advanced glycosylation end products and chronic complications of diabetes mellitus].
    Méndez JD
    Gac Med Mex; 2003; 139(1):49-55. PubMed ID: 12666409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycation products and the pathogenesis of diabetic complications.
    Brownlee M
    Diabetes Care; 1992 Dec; 15(12):1835-43. PubMed ID: 1464241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine.
    Booth AA; Khalifah RG; Hudson BG
    Biochem Biophys Res Commun; 1996 Mar; 220(1):113-9. PubMed ID: 8602828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoguanidine and the prevention of leukocyte dysfunction in diabetes mellitus: a direct vital microscopic study.
    Sannomiya P; Oliveira MA; Fortes ZB
    Br J Pharmacol; 1997 Nov; 122(5):894-8. PubMed ID: 9384505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology of peripheral arterial disease in diabetes mellitus.
    Yang SL; Zhu LY; Han R; Sun LL; Li JX; Dou JT
    J Diabetes; 2017 Feb; 9(2):133-140. PubMed ID: 27556728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperglycemia and microangiopathy. Direct regulation by glucose of microvascular cells.
    Kreisberg JI
    Lab Invest; 1992 Oct; 67(4):416-26. PubMed ID: 1434526
    [No Abstract]   [Full Text] [Related]  

  • 18. The biochemistry of the complications of diabetes mellitus.
    Brownlee M; Cerami A
    Annu Rev Biochem; 1981; 50():385-432. PubMed ID: 6168237
    [No Abstract]   [Full Text] [Related]  

  • 19. [The role of arterial collagen nonenzymatic glycosylation (NEG) in the pathogenesis of diabetic macroangiopathy].
    Fu M; Qian R
    Zhonghua Yi Xue Za Zhi; 1991 Apr; 71(4):202-4, 14. PubMed ID: 1650631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycation and cardiovascular disease in diabetes: A perspective on the concept of metabolic memory.
    Yamagishi SI; Nakamura N; Matsui T
    J Diabetes; 2017 Feb; 9(2):141-148. PubMed ID: 27556881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.